{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:02:32Z","timestamp":1782126152304,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2022.03.008","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T02:11:05Z","timestamp":1647051065000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A"],"prefix":"10.1016","volume":"213","author":[{"given":"Kun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2022.03.008_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0010","first-page":"S330","article-title":"Outcome in moderate haemophilia","volume":"12","author":"Den Uijl","year":"2014","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2022.03.008_bb0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/hae.12438","article-title":"Considerations in individualizing prophylaxis in patients with haemophilia A","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/ort.1965.36.suppl-77.01","article-title":"Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B","author":"Ahlberg","year":"1965","journal-title":"Acta Orthop. Scand. Suppl. Suppl."},{"key":"10.1016\/j.thromres.2022.03.008_bb0025","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2516.2005.01124.x","article-title":"Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed","volume":"11","author":"van Dijk","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years\u2019 experience of prophylactic treatment in severe haemophilia a and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.thromres.2022.03.008_bb0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2516.2007.01501.x","article-title":"Identifying and overcoming barriers to prophylaxis in the management of haemophilia","volume":"13","author":"Petrini","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/hae.13892","article-title":"Show me the evidence: effectiveness of low-dose prophylaxis","volume":"26","author":"Gouider","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0045","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia a: interim results from the first 5 years of the Canadian hemophilia primary prophylaxis study","volume":"4","author":"Feldman","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.03.008_bb0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2516.2012.02926.x","article-title":"Short-term low-dose secondary prophylaxis for severe\/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China","volume":"19","author":"Tang","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0055","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood-2012-12-470898","article-title":"Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s","volume":"122","author":"Fischer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.03.008_bb0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/hae.13270","article-title":"Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products","volume":"23","author":"Tegenge","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/hae.13251","article-title":"PK-guided personalized prophylaxis with Nuwiq\u00ae (human-cl rhFVIII) in adults with severe haemophilia a","volume":"23","author":"Lissitchkov","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0075","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3324\/haematol.2013.084038","article-title":"Impact of being underweight or overweight on factor VIII dosing in hemophilia a patients","volume":"98","author":"Henrard","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2022.03.008_bb0080","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/hae.12300","article-title":"Pharmacokinetic analysis of anti-hemophilic factor in the obese patient","volume":"20","author":"Graham","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1538-7836.2007.02503.x","article-title":"Phenotypic heterogeneity in severe hemophilia","volume":"5","author":"van den Berg","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.03.008_bb0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile","volume":"8","author":"Santagostino","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.03.008_bb0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2006.01401.x","article-title":"In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting","volume":"13","author":"Bj\u00f6rkman","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0100","article-title":"A semiquantitative color doppler ultrasound scoring system for evaluation of synovitis in joints of patients with blood-induced arthropathy, insights","volume":"12","author":"Zhang","year":"2021","journal-title":"Imaging."},{"key":"10.1016\/j.thromres.2022.03.008_bb0105","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.thromres.2022.03.008_bb0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hae.12550","article-title":"Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study","volume":"21","author":"Morfini","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0115","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.03.008_bb0120","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/hae.12691","article-title":"Pharmacokinetic properties of BAY 81\u20138973, a full-length recombinant factor VIII","volume":"21","author":"Shah","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0125","first-page":"25(3):e215","article-title":"Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate\u00ae) and BAY 81\u20138973 (Kovaltry\u00ae) in patients with severe or moderate haemophilia a in prophylaxis","author":"Meg\u00edas-Vericat","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/DDDT.S188171","article-title":"Increased branching and sialylation of n-linked glycans correlate with an improved pharmacokinetic profile for BAY 81\u20138973 compared with other full-length rFVIII products","volume":"13","author":"Teare","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.thromres.2022.03.008_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40259-016-0191-4","article-title":"81\u20138973 (Octocog alfa; Kovaltry\u00ae): a review in haemophilia A","volume":"30","author":"Keating","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.thromres.2022.03.008_bb0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ped4.12252","article-title":"Pharmacokinetic variability of factor VIII concentrates in chinese pediatric patients with moderate or severe hemophilia A","volume":"5","author":"Chen","year":"2021","journal-title":"Pediatr. Investig."},{"key":"10.1016\/j.thromres.2022.03.008_bb0145","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.2019000190","article-title":"Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients","volume":"134","author":"Swystun","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.03.008_bb0150","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/hae.12592","article-title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A","volume":"21","author":"Kepa","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0155","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood.V85.11.3150.bloodjournal85113150","article-title":"The affinity and stoichiometry of binding of human factor VIII to von willebrand factor","volume":"85","author":"Vlot","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.03.008_bb0160","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/jth.14469","article-title":"Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia a: is there a difference?","volume":"17","author":"Carcao","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.03.008_bb0165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0039-3400745","article-title":"Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia a","volume":"120","author":"Tiede","year":"2020","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.03.008_bb0170","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MBC.0000000000001028","article-title":"Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis?","volume":"32","author":"Ay","year":"2021","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2022.03.008_bb0175","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.03.008_bb0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0185","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia a: does the classification of the 1950s still stand?","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0190","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia a management","volume":"10","author":"Valentino","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.03.008_bb0195","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia a: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.03.008_bb0200","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.03.008_bb0205","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Riske","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.03.008_bb0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12288-018-0974-5","article-title":"Ultrasonography of knee joint in hemophilia a: what the eyes cannot see","volume":"35","author":"Nag","year":"2019","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.thromres.2022.03.008_bb0215","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1111\/hae.12107","article-title":"Magnetic resonance imaging and ultrasound evaluation of \u201chealthy\u201d joints in young subjects with severe haemophilia A","volume":"19","author":"Minno","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0220","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/hae.13524","article-title":"Diagnostic accuracy of point-of-care ultrasound for evaluation of early blood-induced joint changes: comparison with MRI","volume":"24","author":"Foppen","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.03.008_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2020-048432","article-title":"Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with kovaltry: protocol of the LEAP study","volume":"11","author":"Kun","year":"2021","journal-title":"BMJ Open"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:47:42Z","timestamp":1758736062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":45,"alternative-id":["S0049384822000858"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.03.008","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}